Clinical Trials Logo

Leukemia, Myeloid clinical trials

View clinical trials related to Leukemia, Myeloid.

Filter by:

NCT ID: NCT04747002 Recruiting - Clinical trials for Acute Myeloid Leukemia in Remission

Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.

Start date: June 12, 2020
Phase: Phase 2
Study type: Interventional

This study is an investigator-initiated clinical trial (Phase II) using DSP-7888 for acute myeloid leukemia patients with 1st hematological complete remission (CR). DSP-7888 is a novel cocktail peptide vaccine designed to induce cytotoxic T lymphocytes that recognize Wilms Tumor Gene 1 (WT1) peptides.

NCT ID: NCT04746235 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia

Start date: February 22, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with newly diagnosed acute myeloid leukemia who are not candidates for intensive chemotherapy. Venetoclax may help block the formation of growths that may become cancer. ASTX727 is the combination of a fixed dose of 2 drugs, cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body, and decitabine may block abnormal cells or cancer cells from growing. Giving venetoclax and ASTX727 may help to control the disease.

NCT ID: NCT04726241 Recruiting - Clinical trials for Acute Myeloid Leukemia

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Start date: April 18, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient's leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.

NCT ID: NCT04722952 Recruiting - Clinical trials for Acute Myeloid Leukemia

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

Start date: May 1, 2021
Phase: Phase 3
Study type: Interventional

This is an single center, single arm, phase 3 study to evaluate efficacy and safety of PD-1 Inhibitor combined with DNA methyltransferase inhibitor Azacytidine and HAG regimen for patients with relapsed and refractory acute myeloid leukemia.

NCT ID: NCT04716114 Recruiting - Clinical trials for Acute Myeloid Leukemia (AML)

A Study of SKLB1028 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory (R/R) AML With FLT3-Mutated

ALIVE
Start date: March 24, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized,multicenter, open-label Phase III, clinical study to confirm the efficacy and safety of SKLB1028 in patients with relapsed or refractory(R/R) FLT3-Mutated Acute Myeloid Leukemia(AML)compared to salvage chemotherapy.

NCT ID: NCT04692948 Recruiting - Clinical trials for Acute Myeloid Leukemia

TAA6 Cell Injection In The Treatment of Patients With Relapsed / Refractory Acute Myeloid Leukemia

Start date: December 9, 2019
Phase: N/A
Study type: Interventional

This is a clinical study of TAA6 cell injection in the treatment of patients with relapsed / refractory Acute Myeloid Leukemia . The purpose is to evaluate the safety and effectiveness of CD276 targeted autologous chimeric antigen receptor T cells infusion in patients with relapsed / refractory CD276 positive Acute Myeloid Leukemia.(TAA6 cell injection is a T cell targeting CD276 chimeric antigen receptor)

NCT ID: NCT04691648 Recruiting - Clinical trials for Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Start date: June 17, 2022
Phase:
Study type: Observational

The objective of this study is to describe the observed safety profile of Xospata® 40 mg tablet when administered in patients with relapsed or refractory AML with FLT3 mutation in routine clinical practice in Korea.

NCT ID: NCT04687761 Recruiting - Clinical trials for Leukemia, Myeloid, Acute

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Start date: November 4, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I-II trial based on the combination of three drugs regimen LDAC or Azacitidine + Venetoclax + Quizartinib that in this population could be well tolerated by a sequential type administration. The first objective is to achieve rapid control of the disease, using two different schemes, one based in Azacitidine and the other in LDAC, by dose escalation in phase I of the trial. The second goal is to prevent relapse through a maintenance schedule. Phase II will study the efficacy and safety of the recommended dose for Phase II

NCT ID: NCT04679285 Recruiting - Clinical trials for Acute Myeloid Leukemia

Minimal Residual Disease Evaluation on Cryopreserved Ovarian Fragments in Younger Patients Treated for Acute Myeloid Leukemia

FERTILAM
Start date: April 26, 2021
Phase:
Study type: Observational

Cryopreservation of ovarian cortex represents an option for fertility preservation in patients diagnosed with acute myeloid leukemia and requiring allogeneic stem cell transplantation. This pilot study aims to evaluate the minimal residual disease on ovarian fragments harvested before allogeneic stem cell transplantation at the time of complete remission.

NCT ID: NCT04678401 Recruiting - Clinical trials for Myelodysplastic Syndromes

IS-free Treg HaploHCT

Start date: January 12, 2021
Phase: Phase 1
Study type: Interventional

This research study is evaluating the safety and efficacy of the IS-free Treg-cell graft-engineered haplo transplant method in people with relapsed/refractory and Ultra-high risk acute myeloid leukemia (AML) and/or myelodysplastic syndromes (MDS) receiving a haploidentical donor allogeneic hematopoietic stem cell transplant (HSCT). The names of the study interventions involved in this study are: - Radiation-Total Myeloid and Lymphoid Irradiation (TMLI - Chemotherapy (Fludarabine, Thiotepa, Cyclophosphamide plus Mesna) - Infusion of haplo Treg-enriched donor cells (experimental therapy) - Infusion of unmodified haplo donor T cells (includes cancer-fighting T effector cells) - Infusion of haplo donor CD34+ Peripheral Blood Stem Cells